Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
Stocks in this Quantisnow insightHealth Care
Historical context for ENTX
Across the 29 sessions after earlier ENTX headlines, the stock closed higher 13 times and lower 16 times, with a median move of 4.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ENTX | SPY |
|---|---|---|---|
| Oct 13, 2026 | Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting | -6.0% | -0.0% |
| Oct 8, 2026 | Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting | -0.4% | -0.4% |
| Sep 25, 2026 | Guggenheim initiated coverage on Entera Bio with a new price target | -2.0% | +0.5% |
| Sep 22, 2026 | Cantor Fitzgerald initiated coverage on Entera Bio | +0.7% | -0.0% |
| Sep 18, 2026 | Leerink Partners initiated coverage on Entera Bio with a new price target | -2.3% | -0.1% |
| Aug 27, 2026 | Correction: Entera to Participate in Upcoming Fall Investor Conferencesand 1 other headline that session | -3.4% | +0.7% |
Quantisnow market dataNASDAQ
ENTX
Entera Bio Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2018
Get push alerts for ENTX
Full ENTX profile on Quantisnow Follow ENTX and get a push notification the moment its next story breaks.